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Activity of neprilysin (NEP), the major protease which cleaves amyloid-β peptide (Aβ), is
reportedly reduced in the brains of patients with Alzheimer’s disease (AD). Accumulation of
Aβ generates reactive oxygen species (ROS) such as 4-hydroxynonenal (HNE), and then
reduces activities of Aβ-degrading enzymes including NEP. Xanthorrhizol (Xan), a natural
sesquiterpenoid, has been reported to possess antioxidant and anti-inflammatory proper-
ties. The present study examined the effects of Xan on HNE- or oligomeric Aβ42-induced ox-
idative modification of NEP protein. Xan was added to the HNE- or oligomeric Aβ42-treated
SK-N-SH human neuroblastoma cells and then levels, oxidative modification and enzymatic
activities of NEP protein were measured. Increased HNE levels on NEP proteins and re-
duced enzymatic activities of NEP were observed in the HNE- or oligomeric Aβ42-treated
cells. Xan reduced HNE levels on NEP proteins and preserved enzymatic activities of NEP
in HNE- or oligomeric Aβ42-treated cells. Xan reduced Aβ42 accumulation and protected
neurones against oligomeric Aβ42-induced neurotoxicity through preservation of NEP ac-
tivities. These findings indicate that Xan possesses therapeutic potential for the treatment
of neurodegenerative diseases, including AD, and suggest a potential mechanism for the
neuroprotective effects of antioxidants for the prevention of AD.
Introduction
Alzheimer’s disease (AD) is a progressive and irreversible neurodegenerative disorder characterized by
cognitive decline [1,2]. AD is also characterized morphologically by extensive amyloid deposition, neu-
rofibrillary tangles, and neuroinflammation leading to synaptic and neuronal loss [3,4]. Oligomeric forms
of amyloid-β peptide (Aβ) aggregate and form senile plaques in the brains of patients with AD [5,6]. Ab-
normal accumulation of Aβ is toxic to neurones [7,8]. Hence, treatments that prevent Aβ accumulation
could slow the neurodegeneration and cognitive decline in AD.
Increasing evidence has shown that Aβ accumulation enhances its production and decreases
its degradation through the actions of several Aβ-degrading enzymes, including neprilysin (NEP),
insulin-degrading enzyme, and endothelin-converting enzyme [9-12]. NEP, a predominant Aβ protease,
cleaves both monomeric and oligomeric forms of Aβ in the brain [13-15]. NEP protein levels are reduced
in the hippocampus and cortex of aged mice [16,17], and NEP is selectively down-regulated in areas of
the AD brain with high levels of amyloid plaques [18,19]. Conversely, overexpression of NEP reduces Aβ
levels in a dose-dependentmanner [20,21], and protects neurones fromAβ-induced toxicity in vitro [22].
These results imply an inverse correlation between NEP activity and Aβ levels, supporting the hypothesis
that a reduction in NEP expression or its activity induces Aβ deposition, and the subsequent neuronal
dysfunction occurs in AD.
c© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 1. Xan prevents HNE-induced NEP modification
HNE-treated (10 μM) SK-N-SH cells were incubated with Xan (1, 10 μM) or NAC (10, 100 μM) and then immunoblot and immuno-
precipitation was followed. (A) A representative NEP immunoblot (top). Any treatment did not change total protein levels of NEP
(bottom). (B) Effects of Xan or NAC on the HNE-induced modification of NEP. A representative HNE immunoblot (top). Xan reduced
HNE-induced increases in HNE levels on NEP (bottom). (C) Untreated cells (a, b, c, d), cells with HNE only (e, f, g, h), cells with
HNE and 10 μM Xan (HNE + Xan; i, j, k, l), and cells with HNE and 100 μM NAC (HNE + NAC; m, n, o, p) were immunostained with
anti-NEP (green) or anti-HNE (red) antibodies. The nuclei were also stained with DAPI (blue). Cellular localization was determined by
confocal overlay imaging. Evidently, Xan reduced HNE-positive signals in HNE-treated cells. Scale bar: 10 μm; mean +− S.E.M. from
three independent experiments; ***P<0.001 compared with untreated controls; #P<0.05, ##P<0.01 compared with HNE–treated
cells.
Oxidative stress has long been recognized as an important factor in the early development of AD [23-25]. Aβ
induces high levels of reactive oxygen species (ROS) [26]. Specifically, elevated levels of 4-hydroxynonenal (HNE),
anα,β-unsaturated hydroxyalkenal that is produced by lipid peroxidation in Aβ deposits could interact with,modify,
and inactivate a variety of cellular proteins and enzymes [27,28]. It has been reported that NEP is modified by HNE
and catalytic activity of HNE-modified NEP is decreased in AD brains and in HNE- or Aβ-treated cells [29,30].
Therefore, it is expected that prevention of NEP oxidative modification may increase NEP activity and increased
NEP activity may reduce Aβ accumulation, which in turn results in protection of neurones against Aβ-induced
neurotoxicity.
Antioxidants have been reported as promising treatments for protecting neurones against oxidative stress [31,32].
Xanthorrhizol (Xan), isolated from Curcuma xanthorrhiza RoxB, has been reported to possess antibacterial and
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Figure 2. Xan inhibits oligomeric Aβ42-induced NEP modification in SK-N-SH cells
Aβ42-treated (1 μM) SK-N-SH cells were incubated with Xan (1, 10 μM) or NAC (10, 100 μM) and then immunoblotting and co-im-
munoprecipitation followed. (A) A representative NEP immunoblot (top). Any treatment did not change total protein levels of NEP
(bottom). (B) Effects of Xan or NAC on the Aβ42-induced modification of NEP. A representative immunoblot for HNE (top). Xan
reduced Aβ42-induced increases in HNE levels on NEP (bottom). (C) Untreated cells (a, b, c, d), cells with 1 μM oligomeric Aβ42
only (e, f, g, h), cells with Aβ42 and 10 μM Xan (Aβ + Xan; i, j, k, l), and cells with Aβ42 and 100 μM NAC (Aβ + NAC; m, n, o, p) were
immunostained with anti-NEP (green) or anti-HNE (red) antibodies. The nuclei were also stained with DAPI (blue). Cellular localiza-
tion was determined by confocal overlay imaging. Evidently, Xan reduced HNE-positive signals in Aβ42-treated cells. Scale bar:
10 μm; mean +− S.E.M. from three independent experiments; ***P<0.001 compared with untreated controls; #P<0.05, ##P<0.01
compared with Aβ42-treated cells.
anti-inflammatory activity [33]. It is also reported that Xan has antioxidant properties, i.e. it directly scavenges hy-
drogen peroxide, it prevents ROS production and ROS-induced cell death, and it inhibits oxidative damage by re-
ducing lipid peroxidation of cellular proteins [34]. Therefore, the present study examined effects of Xan on the ox-
idative NEP modification and NEP activities in HNE- or oligomeric Aβ42-treated neuroblastoma cells, along with
N-acetyl-l-cysteine (NAC) that has been reported to reduce Aβ42-mediated oxidative modification [35].
Materials and methods
Cell culture and treatment
Human neuroblastoma SK-N-SH cells were obtained from the American Type Culture Collection (ATCC, HTB-11,
Manassas, VA) and maintained in essential medium supplemented with 1 μM non-essential amino acids, 100 UI/ml
penicillin, 100 μg/ml streptomycin, and 10% (v/v) FBS (all culture materials from Invitrogen, Carlsbad, CA) in a
humidified atmosphere with 5% CO2 at 37◦C. Cells were subcultured twice per week and had undergone four to
eight passages prior to the experiments.
c© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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A combination of HNE (Cayman Chemical, Ann Arbor, MI), Xan (Enzo Life Sciences, Farmingdale, NY), NAC
(Sigma–Aldrich, St. Louis, MO), oligomeric Aβ42 (AnaSpec, Fremont, CA), or thiorphan (TP, Cayman Chemical), a
specific NEP inhibitor, was added to the cultured cells according to experimental design.Xan andNACwere dissolved
and diluted in Dulbecco’s PBS (DPBS, pH 7.4). HNE and TPwere freshly prepared in DMSO and diluted in PBS prior
to the experiment. To induce oxidative modification of NEP, cells were kept in 2% serum-reduced medium for 16 h,
and HNE (10 μM) or oligomeric Aβ42 (1 μM) were then added to the cultured cells for 12 h. The same volume PBS
was added to the cultures to serve as untreated controls.
Preparation of Aβ42
Monomeric and oligomeric Aβ42 were prepared as described previously [36], from aliquots of the same batch of Aβ42.
For oligomericAβ42, lyophilizedAβ42 aliquots (0.3mg)weredissolved in 0.2mlof 1,1,1,3,3,3-Hexafluoro-2-propanol
(HFP, Sigma–Aldrich) and then added to 0.7 ml H2O. Samples were loosely capped and stirred on a magnetic stir-
rer under a fume hood for 48 h, and used within 36 h. Monomeric Aβ42 was prepared immediately before use by
rapidly evaporating the HFP via gentle bubbling of nitrogen gas into the solution. The quality of Aβ42 preparations
was checked by immunoblot with anti-A-11 (1:1000, Invitrogen) and anti-6E10 (1:1000, Covance, Princeton, NJ)
antibodies.
Immunoprecipitation and immunoblot analysis
Cultured cells were lysed in cold lysis buffer (10 mM Tris/HCl, pH 7.4, 5 mM EDTA, 1% Triton X-100, 10% glycerol,
1 mM CaCl2, 1 mM MgCl2, and 1× complete protease inhibitor cocktail (Thermo Scientific, Waltham, MA)) for 1
h at 4◦C. Total lysates (1 mg) were immunoprecipitated with an anti-NEP antibody (1 μg/ml, Abcam, Cambridge,
MA) at 4◦C overnight, and protein/antibody immunocomplexes were purified with protein A-magnetic beads and
a magnetic separator (both from Millipore, Temecula, CA). After washing, immunocomplexes were separated by
SDS-PAGE using 10% gels (Invitrogen), transferred on to nitrocellulose membranes, and incubated with the primary
rabbit polyclonal anti-HNE or rabbit polyclonal anti-NEP (both from Millipore) antibodies at room temperature
overnight. After incubation with the secondary horseradish peroxidase (HRP)-conjugated goat anti-rabbit or mouse
IgG (1:10000; Jackson ImmunoResearch Lab, West Grove, PA) antibodies, the membranes were developed with ECL
and exposed to X-ray film (Thermo Scientific). As a control, membranes were stripped and re-probed with the pri-
mary mouse anti-NEP (1:1000, Abcam) or mouse anti-β-actin (1:4000, Sigma–Aldrich) antibodies followed by the
secondary HRP-conjugated goat anti-mouse IgG (1:10000, Jackson ImmunoResearch Lab) antibody. Immunoreac-
tivity was assessed by densitometric analysis of films using an HP Scanjet densitometer (Hewlett-Packard, Corvallis,
OR) and ImageJ image analysis software (1.47v, NIH, Bethesda, MD) as described previously [37].
Immunocytochemistry
Cells grown on 2% gelatin (Sigma–Aldrich) coated coverslips (Carolina Biological Supply Company, Burlington, NC)
were fixed with 4% paraformaldehyde at room temperature for 20 min and permeabilized with 0.2% Triton X-100
in 1× PBS (pH 7.4). After pre-blocking for 1 h at room temperature with 1% normal goat serum/1× PBS, cells were
incubated overnight at 4◦C in a humidified chamber with the primary mouse anti-NEP (1:100, Abcam) or rabbit
anti-HNE (1:200, Millipore) antibodies. At the end of the incubation period, the cells were rinsed three times with
1× PBS containing 0.05% Tween-20 (PBS-T) and then incubated with the secondary Alexa 488-conjugated goat
anti-mouse or Alexa 568-conjugated goat anti-rabbit IgG (1:500, Invitrogen) for 60 min at room temperature. All
primary and secondary antibodies were diluted in PBS-Twith 2% normal goat serum. After rinsing with 1× PBS, the
coverslipsweremounted using ProLongGold antifade reagentwithDAPI (Invitrogen), and viewed and photographed
on a Zeiss LSM 710 laser scanning confocal microscope (Carl Zeiss, Thornwood, NY). Immunofluorescence staining
was repeated at least three times.
Fluorometric NEP activity assay in cell lysates and intact cells
To determine NEP activity in whole cell lysates, cells were incubated with HNE (10 μM) or oligomeric Aβ42 (1 μM)
without or with Xan (1, 10 μM) or NAC (10, 100 μM) for 12 h, collected, lysed in 1× PBS (pH 7.4) with 0.1% Triton
X-100, and the lysates were placed on ice for 30 min. NEP activity in cell lysates was analyzed using a synthetic
NEP fluorogenic peptide substrate (Mca-R-P-P-G-F-S-A-F-K[Dnp]-OH; R&D Systems, Inc., Minneapolis, MN) in
the presence/absence of 500 nMTP. Samples were dissolved in 50mM HEPES buffer (pH 7.5) and pre-incubatedwith
TP or 1× PBS for 20 min prior to adding the NEP fluorogenic peptide substrate (dissolved in HEPES). Fluorescence
was read at 320 nm excitation and 405 nm emission on a fluorescent microplate reader (BioTek, Winooski, VT).
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Figure 3. Xan prevents HNE- and oligomeric Aβ42-induced reduction in NEP activity in SK-N-SH cells
HNE-treated (10 μM) SK-N-SH cells were incubated with Xan (1, 10 μM) or NAC (10, 100 μM) and then NEP activities of whole
cell lysates (A) and intact cells (B) were measured, using a fluorometric peptide substrate. Xan and NAC treatments prevented the
HNE-induced reduction in NEP activity. Aβ42-treated (1 μM) SK-N-SH cells were incubated with Xan (1, 10 μM) or NAC (10, 100
μM) and then NEP activities of whole cell lysates (C) and intact cells (D) were measured. Xan and NAC prevented the oligomeric
Aβ42-induced reduction in NEP activity. Average NEP activity was expressed as a percentage of the untreated control. Mean +−
S.E.M. for three independent experiments; *P<0.05, **P<0.01 compared with untreated controls; #P<0.05, ##P<0.01 compared
with HNE- or Aβ42-treated cells.
The activity of membrane-bound NEP in intact cells was measured as previously described [36]. Briefly, af-
ter treatment like above, intact cells were harvested, washed with 1× PBS (pH 7.4), and incubated with 1 mM
glutaryl-Ala-Ala-Phe-4-methoxy-2-naphthylamide (Sigma–Aldrich) as the NEP substrate. The substrate solution
was collected and incubated with leucine aminopeptidase (50 μg/ml, Sigma–Aldrich, St. Louis, MO, U.S.A.) in the
presence/absence of 500 nM TP for 30 min at 37◦C, and the released free 4-methoxy-2-naphthylamide was fluoro-
metrically measured at an emission wavelength of 425 nm using a microplate reader (BioTek).
FRET assay was performed for kinetic analyses of NEP activity. Cell lysates prepared by the method described
above were incubated with increasing concentrations of NEP fluorogenic peptide substrate (0–20 μM) at room tem-
perature. Fluorescence wasmeasured over a 1-h period. NEP activity was determined as the difference in fluorescence
in the presence/absence of 500 nM TP. Kinetic isotherms (Vmax and Km values) for NEP activity were determined
by non-linear least squares fitting to the Michaelis–Menten equation using GraphPad Prism 6 software (GraphPad
Software, Inc., La Jolla, CA).
c© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 4. Xan enhances Vmax and Km values of NEP enzymatic activity in SK-N-SH cells
(A) NEP activity in untreated cells, cells with HNE (10 μM), cells with HNE and Xan (10 μM), and cells with HNE and NAC (100 μM)
was determined using FRET assay. (B) NEP activity in the untreated cells, the cells with oligomeric Aβ42 (1 μM), the cells with Aβ42
and Xan (10 μM), and cells with Aβ42 and NAC (100 μM) was determined using FRET assay. The dependence of the mean NEP
activity on increasing substrate concentration (0–20 μM) in SK-N-SH lysates was measured using FRET assay, and then the Vmax
and Km values (C) were calculated. The NEP Km values were decreased by HNE or oligomeric Aβ42 treatments and preserved by
Xan or NAC pre-treatment. Mean +− S.E.M. from three independent experiments.
In vitro Aβ cleavage assay
SK-N-SH cells were incubated with Xan (1, 10 μM) or NAC (10, 100 μM), in the presence/absence of 500 nM TP
for 1 h. NEP proteins were isolated by immunoprecipitation from cells. For the in vitro cleavage assay, isolated NEP
proteins were incubated with the same amount of 2.5 μM monomeric or oligomeric Aβ42 in 20 mM HEPES, pH 7.4,
10 mM KCl, and 10 mM MgCl2 for an additional 4 h at 30◦C. The reaction mixture was separated on SDS/PAGE
(10–20% gel) (Invitrogen), blotted, and probed with anti-6E10 antibody (1:1000, Covance) as described in ‘Immuno-
precipitation and immunoblot analysis’ section.Cleavage ofAβ42 wasdiscernedby thedisappearance of protein bands
corresponding to intact monomeric and oligomeric Aβ42. The densities of the remaining Aβ42 bands were quanti-
tated using an HP Scanjet densitometer and ImageJ image analysis software, and plotted using GraphPad Prism 6
software.
Cell toxicity assay
Cells were cultured in 48- or 96-well plates at a density of ∼3000–5000 cells/well in complete growth medium for
24 h. Growth medium was replaced with fresh culture medium (∼100–200 μl/well) containing 2.0% FBS and 1 μM
oligomeric Aβ42 for 24 h. Another batch of cells were co-treated with Xan or NAC in the presence/absence of 500
nM TP. After 24 h, a cell viability assay was performed as described previously [34,36] using the Cell Counting Kit-8
(Dojindo, Rockville, MD). Briefly,∼10–20 μl of CCK-8 solution was added to all wells, and the plates were incubated
for 4 h at 37◦ C in 5% CO2. The culturemediumwas collected and detectedwith amicroplate reader at a wavelength of
450 nm. The difference in optical density (OD) relative to untreated controls was taken as a measure of cell viability,
and the percentage of viable cells was calculated by comparing the OD at 450 nm for the Aβ42-treated and control
wells.
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Statistical analysis
Data were expressed with a percentage of untreated controls. All data are presented as mean +− S.E.M. from three
or more independent experiments, unless otherwise indicated. Differences between untreated cells and HNE- or
oligomeric Aβ42-treated cells were examined using a t test. One-way ANOVAwas conducted to see the effects of Xan
and NAC on conditions with these experimental treatments. Subsequent post hoc test (Tukey’s multiple comparison)
was followed. P-values less than 0.05 were considered significant, unless specified otherwise.
Results
Xan prevented HNE-induced NEP modification
Effects of Xan and NAC on the HNE-treated SK-N-SH cells were examined by measurements of oxidative modi-
fication of NEP (Figure 1). Any treatment did not change total NEP levels (Figure 1A). However, HNE treatment
markedly increased HNE levels on NEP proteins (t(10) =9.73, P<0.001; Figure 1B), which was effectively reduced
by 1 μM Xan treatment by 38%; 10 μM Xan reduced 59% HNE levels on NEP proteins in the HNE-treated cells
(F(2,15) =11.74, P<0.01); 10 and 100 μM NAC also reduced 36 and 49% HNE levels on NEP proteins, respectively,
in the HNE-treated cells (F(2,15) =11.17, P<0.01; Figure 1B).
Furthermore, we observed that HNE-induced HNE increases on NEP proteins using double immunofluorescence
staining. As shown in Figure 1C, HNE-positive signals were undetectable in untreated controls, but were abundant
and co-localized with NEP-positive signals in the HNE-treated cells. Both 10 μM Xan and 100 μM NAC treatments
reduced the HNE-positive signals in the HNE-treated cells.
Xan prevented oligomeric Aβ42-induced HNE modification of NEP
Effects of Xan and NAC on the oligomeric Aβ42-treated SK-N-SH cells was examined by measurements of oxidative
modification of NEP (Figure 2). Any treatment did not change total NEP levels (Figure 2A). However, oligomeric
Aβ42 treatments markedly increased HNE levels on NEP proteins (t(10) =9.04, P<0.001; Figure 2B); 1 and 10 μM
Xan treatments decreased 47 and 75% HNE levels on NEP proteins in the oligomeric Aβ42-treated cells, respectively
(F(2,15) =11.83, P<0.01); 10 and 100 μM NAC treatments also reduced 42 and 70% HNE levels on NEP proteins in
the oligomeric Aβ42-treated cells, respectively (F(2,15) =8.57, P<0.01; Figure 2B).
Furthermore, we observed oligomeric Aβ42-induced HNE increases on NEP proteins using double immunoflu-
orescence staining. As shown in Figure 2C, HNE-positive signals were undetectable in untreated controls, but were
abundant and co-localized with NEP-positive signals in the oligomeric Aβ42-treated cells. Both 10 μM Xan and 100
μM NAC treatments reduced the HNE-positive signals in the oligomeric Aβ42-treated cells.
Xan protected HNE- or oligomeric Aβ42-induced NEP inactivation
HNE treatment induces NEP modification, resulting in inactivation of NEP protein. Therefore, it is predicted that
prevention of either HNE- or oligomeric Aβ42-induced NEP modification would preserve NEP activity. The present
experiment examined the changes in NEP activity in HNE- or oligomeric Aβ42-treated SK-N-SH lysates and intact
cells, using a fluorometric peptide substrate. Exogenous treatment of 10 μM HNE into cells led to a significant loss of
NEP activity, by 51% in whole cell lysates (t(20) =5.45, P<0.05; Figure 3A) and by 61% in intact cells (t(20) =7.16,
P<0.01; Figure 3B). However, 1 and 10 μM Xan treatments increased 35 and 49% NEP activities in the HNE-treated
cell lysates, respectively (F(2,30) =9.90, P<0.05). In addition, 1 and 10 μM Xan treatments increased 41 and 60%
NEP activities in the HNE-treated intact cells, respectively (F(2,30)=16.26, P<0.01). Similar patterns were observed
in the NAC experiments: 10 and 100 μM NAC treatments increased 37 and 52% NEP activities in the HNE-treated
cell lysates, respectively, (F(2,30)=6.81, P<0.05; Figure 3A), and 35 and 59%NEP activities in theHNE-treated intact
cells, respectively (F(2,30) =8.24, P<0.01; Figure 3B).
Since oligomeric Aβ42 increases endogenous generation of HNE and subsequently leads to HNE-induced mod-
ifications in NEP, we measured NEP activity in oligomeric Aβ42-treated cells (Figure 3C,D). Similar to results of
HNE-treated cells, oligomeric Aβ42 decreased 53% NEP activities in whole cell lysates (t(18) =5.86, P<0.05; Figure
3C) and 65% NEP activities in intact cells (t(18) =7.56, P<0.01; Figure 3D); 1 and 10 μM Xan treatments recov-
ered 32 and 52% NEP activities in the Aβ42-treated whole cell lysates (F(2,27) =11.74, P<0.05); 36 and 59% in the
Aβ42-treated intact cells (F(2,27) =17.05, P<0.01); 10 and 100 μM NAC treatments also recovered 23 and 40% NEP
activities in the Aβ42-treated whole cell lysates, respectively (F(2,27) =3.93, P<0.05); 15 and 57% in the Aβ42-intact
cells, respectively (F(2,27) =9.18, P<0.01).
c© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
License 4.0 (CC BY).
7
D
ow
nloaded from
 https://portlandpress.com
/bioscirep/article-pdf/38/1/BSR
20171611/430111/bsr-2017-1611-t.pdf by guest on 20 April 2020
Bioscience Reports (2018) 38 BSR20171611
https://doi.org/10.1042/BSR20171611
Figure 5. Xan enhances NEP-mediated Aβ42 degradation
NEP proteins were isolated from untreated cells, cells with Xan (1, 10 μM), cells with TP (500 nM) + Xan (10 μM), cells with NAC
(10, 100 μM), and cells with TP + NAC (100 μM), using immunoprecipitation. These isolated NEP proteins were incubated with
monomeric (A) and oligomeric (B) Aβ42 (2.5 μM). The densities of the Aβ42 bands were quantitated. Xan and NAC decreased
monomeric and oligomeric Aβ42 levels. However, TP, an NEP inhibitor, abolished the effects of Xan and NAC on the Aβ42 degrada-
tion. Mean +− S.E.M. for three independent experiments; *P<0.05; **P<0.01 compared with untreated cells; ##P<0.01 compared
with Xan (10 μM)- or NAC (100 μM)-treated cells.
To further characterize the effect of Xan onNEP activation, we used a range of NEP substrate concentrations (0–20
μM) in SK-N-SH cells and thenmeasuredNEP activity using a FRET assay. Themeasurement ofNEP activity was sat-
urable and followed Michaelis–Menten kinetics in all cell samples (Figure 4). TheVmax of NEP activity was decreased
in the HNE- or oligomeric Aβ42-treated cells; 1 μM Xan pre-treatment cells slightly normalized the Vmax in the
HNE- or oligomeric Aβ42-treated cells, but it was not statistically significant, compared with the HNE- or oligomeric
Aβ42-treated cells; however, 10 μM Xan completely recovered the Vmax (Figure 4A,B); 100 μM NAC treatment had
a similar effect on the recovery of the Vmax of NEP activity (Figure 4A,B). Lineweaver–Burk double-reciprocal plots
of the reaction velocities and substrate concentrations permitted calculation of the Michaelis constant (Km) for the
enzyme in all samples. The NEP Km values were decreased by HNE or oligomeric Aβ42 treatment and recovered by
Xan or NAC pre-treatment (Figure 4C).
Xan enhanced the ability of NEP to degrade Aβ42 peptide and the
resistance of SK-N-SH cells to Aβ42-induced neurotoxicity through NEP
activation
The present experiment examined the effect of Xan though NEP action on the degradation of Aβ42; 1 and 10 μM
Xan treatments decreased 54 and 72% monomeric Aβ42 levels, respectively, compared with the untreated control
(F(2,15) =69.57, P<0.01). Similarly, 10 and 100 μM NAC treatments decreased 52 and 71% monomeric Aβ42 levels,
respectively, compared with the untreated control (F(2,15) =74.81, P<0.01); 500 nM TP, an NEP inhibitor, almost
completely abolished the effect ofXan (t(10)=9.739, P<0.01) andNAC (t(10)=13.61, P<0.01) on Aβ42 degradation
(Figure 5A). Notably, 1 and 10 μM Xan treatments cleaved oligomeric Aβ42 by approximately 46 and 63%, respec-
tively, compared with the untreated control (F(2,15) =57.96, P<0.01). And 10 and 100 μM NAC reduced 37 and
56% oligomeric Aβ42 levels, respectively, compared with the untreated control (F(2,15)=47.18, P<0.01); 500 nM TP
completely abolished the effect of Xan or NAC on oligomeric Aβ42 cleavage (Figure 5B).
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Figure 6. Xan protects against Aβ42-induced neuronal toxicity in SK-N-SH cells
The viabilities of untreated cells, cells with oligomeric Aβ42 (1 μM), cells with oligomeric Aβ42 + Xan (1, 5, 10 μM), cells with
oligomeric Aβ4 + Xan (10 μM) + TP (500 nM), cells with oligomeric Aβ42 + NAC (10, 50, 100 μM), and cells with oligomeric Aβ42 +
NAC (100 μM) + TP, was determined. Viabilities of oligomeric Aβ42-treated cells evidently were decreased compared with untreated
cells (**). Xan and NAC increased cell viabilities of Aβ42-treated cells in a dose-dependent manner, but these Xan and NAC effects
was abolished by TP, an NEP inhibitor. Data are expressed as the percentage of untreated cells. Mean +− S.E.M. of three inde-
pendent experiments; P<0.01 compared with untreated controls; #P<0.05, ##P<0.01 compared with Aβ42-treated cells; $$P<0.01
compared with Aβ42 + Xan or Aβ42 + NAC-treated cells.
We examined the protective effects ofXan orNAC against oligomericAβ42-inducedneurotoxicity via theirNEP ac-
tion.Oligomeric Aβ42-treated SK-N-SH cells were incubatedwithXan or NAC in the presence/absence of TP. The vi-
abilities of neuroblastoma cells were significantly decreased by the oligomeric Aβ42 treatment (t(14)=9.28, P<0.01).
But Xan and NAC treatments increased the viabilities of the oligomeric Aβ42-treated cells in a dose-dependent man-
ner; 1, 5, and 10 μM Xan increased 5, 30, and 40% viabilities, respectively (F(3,28) =11.94, P<0.01), and 10, 50, and
100 μM NAC increased 5, 16, and 36% viabilities (F(3,28) =7.73, P<0.01). NEP inhibition by TP almost completely
abolished the protective effect of Xan (t(14) =4.63, P<0.01) or NAC (t(14) =3.41, P<0.01) on cell viability (Figure
6).
Discussion
During ageing and in neurodegenerative diseases including AD, oxidative stress such as excess reactive HNE re-
sults in modification of membrane lipids, DNA, and cellular proteins, which in turn alter their function [2,24,25].
HNE-modified proteins are abundant in the brains of AD patients, suggesting a role of oxidative damage inAD patho-
genesis [26,27,35,38]. For example, increased HNE levels on NEP proteins and decreased activities of HNE-modified
NEP in Aβ deposits have been observed in the AD brain [30,35]. Experimental evidences have demonstrated that
NEP, a major Aβ-degrading enzyme, is one of HNE-induced oxidized proteins [29,30]. Therefore, one of potential
strategies for preventing AD is an administration of antioxidants that inhibit HNE-induced NEP modification and
prevent the loss of NEP activity [32]. Hence, the present study examined the effects of the antioxidants on HNE- or
Aβ-induced NEP modification and activity, and subsequently demonstrated their protective effects through actions
on NEP against Aβ42-induced neurotoxicity.
Xan is the most active compound isolated from C. xanthorrhiza RoxB, possessing several biological activities
including antioxidant and anti-inflammatory effects [31]. Specifically, our previous study showed that Xan has
anti-inflammatory activity, i.e. it inhibits pro-inflammatory cytokines, such as interleukin-6 and tumor necrosis
factor-α, and inhibits nitric oxide (NO) production in lipopolysaccharide-activated microglial cells [34]. In addition,
c© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
License 4.0 (CC BY).
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Xan reduces the expression of cyclooxygenase-2 and inducible nitric oxide synthase (iNOS), which results in reduc-
tion in NO in activated microglial cells [34]. Xan has potent neuroprotective effects against glutamate-induced neu-
rotoxicity and ROS generation in hippocampal HT22 cells, and inhibits lipid peroxidation in rat brain homogenates
with H2O2 treatments [34]. Therefore, it is expected that Xan, an antioxidant, could inhibit HNE-induced modifi-
cation of the NEP protein. Both exogenous HNE treatments and the induction of endogenous HNE by oligomeric
Aβ42 increased HNE levels on NEP proteins. These results are consistent with previous reports that Aβ increased the
production of HNE and free radicals in neurones [35,39]. Importantly, Xan reduced HNE levels on NEP proteins in
HNE- or Aβ42-treated cells. NAC as a positive control showed similar results.
Aβ peptide plays a pivotal role in the pathogenesis of AD [10,12]. Aβ- or oxidant-induced HNE modification
reduces the activity of both endogenous and recombinantNEPprotein [30,40], following a reduction inAβ-degrading
ability of NEP and Aβ accumulation [29,30]. It is also confirmed in our previous study that the activity of NEP was
reduced in oligomeric Aβ42-treated cells [36]. Thus, reduction in NEP activity likely accelerates the development
and progression of AD [29,40]. On the contrary, enhancement of Aβ-degrading enzyme activity would promote Aβ
degradation [13,22]. In the present study,Xan andNACprevented the inactivation ofNEPbyHNEor oligomericAβ42
treatment. Vmax and Km analyses revealed that NEP activity followed Michaelis–Menten kinetics, with a hyperbolic
dependence of v (velocity) on substrate concentration. HNE or oligomeric Aβ42 decreased Vmax and Km of NEP
activity, whereas Xan or NAC restored Vmax and Km of NEP activity in cells with HNE or oligomeric Aβ42 treatments.
These results suggest that a reduction in NEP activity by HNE could be reversed by antioxidants. Furthermore, the
present experiment demonstrated that Xan or NAC treatments degraded bothmonomeric and toxic oligomeric Aβ42
and protect neuronal cells against oligomeric Aβ42-induced toxicity via enhancing NEP activity.
Numerous studies have demonstrated that direct antioxidants, such as flavonoids, indirect antioxidants, such as
NOS inhibitors, andmetabolic antioxidants, such as NAC, can prevent neurodegeneration in AD [41,42]. The present
results indicate that these actions are related to the protection of the Aβ-degrading enzyme NEP from oxidative
modification and inactivation. Though NEP is a major physiological Aβ-degrading enzyme, several other enzymes
such as angiotensin-converting enzyme also degrade Aβ peptides [9,14,15,20]. Future studies will examine roles of
these Aβ-degrading enzymes in oxidative modification and Aβ-degrading activity, and effects of antioxidants on
these enzymes.
However, amyloid plaque composed of Aβ is one of two major pathological features in AD. Even though if it is
limited to the amyloid cascade hypothesis, aggregation of Aβ evokes oxidative damage, inflammation, and neuro-
toxicity. Oxidative damage contributes to inflammation in AD and Aβ-induced neurotoxicity is exacerbated under
inflammation dysregulation [7, 23]. The present study proved only the possibility of Xan as an antioxidant treatment
of AD. Because, as already reported, Xan has a variety of biological activities such as anti-inflammatory properties
[31]. These properties and efficacies of Xan need to be studied using primary cultured neurones in vitro as well as in
vivo in the brains of AD animal models with several pathological features of AD, with research to reveal its molecular
and cellular mechanism.
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